Inhibition of Tacrolimus Metabolism by Cannabidiol and Its Metabolites In Vitro

Inhibition of Tacrolimus Metabolism by Cannabidiol and Its Metabolites In Vitro

ABSTRACT Drug interactions are major causes of interindividual variability in tacrolimus exposure and effect. Tacrolimus, a widely used drug in transplant patients, is metabolized by CYP3A4 and CYP3A5. Cannabidiol (CBD) use after transplant is common. Clinical cases suggest CBD may alter tacrolimus...

Full description

Bibliographic Details
Main Authors: Gerald C. So, Jessica Bo Li Lu, Ying‐Hua Cheng, Debora L. Gisch, Sachiko Koyama, Ricardo Melo Ferreira, Travis R. Beamon, Zeruesenay Desta, Michael T. Eadon
Format: Article
Language:English
Published: Wiley 2025-02-01
Series:Clinical and Translational Science
Subjects:
cannabinoid
CYP
drug–drug interactions
pharmacokinetics
Online Access:https://doi.org/10.1111/cts.70152

Internet

https://doi.org/10.1111/cts.70152

Similar Items